Publicador de contenidos

Chagas

FEXI 12

Oral fexinidazole dosing regimens for the treatment of adults with chronic indeterminate Chagas disease

Foto: DNDi
Duración
04/10/2017 - 31/12/2018
Coordinador
Joaquim Gascon
Financiadores
DNDi

Phase 2 Randomized, Multicenter, Double-blinded Safety and Efficacy Study

The general objective of this clinical trial is to determine the efficacy and safety of alternative dosing regimens of FEXI in reducing and clearing T. cruzi parasitemia in adult individuals with the chronic indeterminate Chagas Disease, in comparison to historical placebo control.

This is  a double-blind, randomized, prospective, comparative, pharmacokineticpharmacodynamic, and proof-of-concept trial design, with three-parallel groups and historical placebo control. The trial will be conducted in 5 different sites in Spain. The trial will be sufficiently powered to compare the efficacy and safety of each of the dosing regimens of FEXI with historical placebo control. Efficacy and safety will be monitored by an external independent Data Monitoring Committee (DMC) on an ongoing basis. The committee is to include cardiac and liver safety experts, as well as Chagas Disease clinical expertise.

The total duration of patient trial participation will be approximately 14 months.

Nuestro equipo

PI

  • Joaquim Gascon Brustenga
    Joaquim Gascon Brustenga

ISGlobal team

Ver más

Otros proyectos

Ver proyectos pasados

MESA

La Alianza Científica para la Erradicación de la Malaria (MESA) tiene como objetivo avanzar en la ciencia de la erradicación de la malaria.

NHEPACHA

Nuevas Herramientas para el Diagnóstico y la Evaluación del Paciente con Enfermedad de Chagas

Estudio inmunológico de la vacuna RTS,S

Estudio de correlatos de protección frente a la malaria después de la vacunación con RTS,S/AS01E: Una evaluación inmunológica exhaustiva en el ensayo clínico de Fase III, doble ciego, aleatorizado, multicéntrico con un grupo control

Euroleish.net

Control of Leishmaniasis. From bench to bedside and community

GREPIMER

Grup de recerca en patología importada i malaties emergents i re-emergents

TESEO

Nuevos regímenes de quimioterapia y biomarcadores para la enfermedad de Chagas

ASINTMAL

Unravelling Disease Tolerance and Host Resistance in Afebrile 'P. falciparum' Infections: a Prospective Study in Mozambican Adults

ADAM

Administración masiva y focal de fármacos antimaláricos para avanzar hacia la eliminación de la malaria en Mozambique: acelerando la implementación de programas y políticas

MULTIPLY

MULTIple doses of IPTi Proposal: a Lifesaving high Yield intervention

Science4Pandemics

Citizens engagement digital platform for collective intelligence in pandemics

HIDDENVIVAX

Novel organ-on-a-chip technology to study extracellular vesicles-mediated cryptic infections in Plasmodium vivax malaria

MENA Migrant Health

Transforming data collection and surveillance to drive migrant health research, care and policy

SexMal

Social affairs and sex in P. falciparum: implications for malaria elimination

EpiGen

Building Scalable Pathogen Genomic Epidemiology in Ethiopia

SMART

Identifying Severe Malaria with a new Aptamer-based Rapid diagnostic Test

MalTransc

Transcriptional regulation of adaptation and developmental decisions in malaria parasites: from epigenetic variation to directed transcriptional responses

GenMoz

P. falciparum genomic intelligence in Mozambique

BOHEMIA

Broad One Health Endectocide-based Malaria Intervention in Africa